Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.

Citations Over TimeTop 1% of 1994 papers

Abstract

Multiple endocrine neoplasia type 2B (MEN 2B) is a human cancer syndrome characterized by medullary thyroid carcinoma (MTC), pheochromocytomas, mucosal neuromas, ganglioneuromas of the intestinal tract, and skeletal and ophthalmic abnormalities. It appears both as an inherited disorder and as de novo disease. Sequence analysis of germ-line DNA from MEN 2B patients revealed the existence of the same point mutation in the RET protooncogene in 34 unrelated individuals. This sequence difference was not observed in 93 unaffected individuals, including the normal parents of 14 de novo MEN 2B patients. The mutation (ATG-->ACG) results in the replacement of methionine with threonine within the catalytic core region of the tyrosine kinase domain. We propose that this amino acid replacement effects substrate interactions and results in dominant oncogenic activity by the RET protein. Missense mutations in the extracellular ligand-binding domain of the RET protooncogene previously have been associated with two other disorders [MEN 2A and familial MTC (FMTC)] in which MTC is observed. MEN 2B represents the third form of heritable MTC known to be an allele of RET. Alterations in two different functional domains of the putative receptor protein tyrosine kinase are implicated in development of MTC.

Related Papers

• → Pheochromocytoma in an 8‐year‐old patient with multiple endocrine neoplasia type 2A: Implications for screening(2013)29 cited
• → Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrine neoplasia, type 2(1980)92 cited
• → Cutaneous metastasis of pheochromocytoma in multiple endocrine neoplasia IIB(2006)12 cited
• → Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcome(2022)1 cited
• → Pheochromocytoma in Multiple Endocrine Neoplasia Type 2(2021)